Genedrive plc (AIM: GDR) has highlighted a new case study published by the National Institute for Health and Care Research examining the development, clinical validation and adoption of its Genedrive
Genedrive plc (AIM: GDR) has highlighted a new case study published by the National Institute for Health and Care Research examining the development, clinical validation and adoption of its Genedrive
Roadside (AIM: ROAD) has reopened its redeveloped Coventry forecourt following a £1.7 million capital investment, while confirming plans to recommend its first dividend.
Genedrive PLC (AIM: GDR) has announced that its Genedrive® MT-RNR1 ID Kit has been implemented at Erasmus MC University Medical Center in Rotterdam, expanding the international adoption of its rapid
genedrive plc (AIM: GDR) expects to report total income of £1.4 million for the year ended 30 June 2026, up from around £1.0 million in FY25 and in line with
Genedrive plc (AIM: GDR) has highlighted comments from UK Health Minister Preet Kaur Gill MP, who cited rapid pharmacogenetic testing for antibiotic-induced hearing loss as a practical example of personalised
genedrive plc (AIM: GDR) has entered into a product development collaboration with Thermo Fisher Scientific to develop a high-throughput CYP2C19 pharmacogenetic test for deployment on Thermo Fisher’s QuantStudio™ 5 Dx
Roadside plc (AIM: ROAD) has reported a transformational first half as the company accelerates its strategy to build a major UK energy forecourt and convenience retail platform through acquisitions.
Proposed Placing and Subscription to raise approximately £20 million to fund acquisition of Gardner Retail Ltd and Proposed Acquisition of D.A. Roberts Fuels Limited
Roadside Real Estate PLC (AIM: ROAD) has agreed a binding deal to acquire Gardner Retail Ltd for an estimated net consideration of £17.8 million, a transaction the company said will
genedrive plc launches new interactive investor hub
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to note the recent media coverage of its Genedrive® MT-RNR1 ID Kit, which reduces the risk of
Genedrive® MT-RNR1 ID Kit implemented at Dublin’s Rotunda Hospital